42 results about "Interactions protein" patented technology

The invention relates to a prediction method of protein interaction direction and regulation relationship, which comprises the following steps: homologous modeling of the interaction protein; comparing and superposing the homologous spatial structure of each interacting protein and each subunit of the protein complex, according to the structure of the stable complex, a protein-protein interactionmodel with spatial structure resolution being constructed, and the interaction direction and frequency of amino acid residues in the protein-protein interaction interface being calculated, and the directional contact map of amino acid residues in the protein-protein interaction interface being generated; a convolution neural network being used to extract the target characteristics of the directional contact map, and the recognition model being trained to obtain the training model, and the protein interaction direction and regulation relationship being predicted. The prediction method of protein interaction direction and regulation relationship is a prediction method based on depth learning, which can achieve accurate and efficient prediction of protein interaction direction and regulationrelationship.

Protein-protein interactions represent a large and important group of drug targets involved in the development and progression of human diseases. However, their utilization in drug discovery has been hampered by the low probability of identifying small-molecule inhibitors able to disrupt protein binding with desirable potency and selectivity. Therefore, the capability for rapid screening of large compound libraries has been critical for the exploration of this target class. The present invention relates to a homogeneous time-resolved fluorescence assay for identification of inhibitors of Cks1-Skp2 binding that plays a critical role in the ubiquitin-dependent degradation of p27. The assay was implemented in a 1536-well format using the new Zeiss uHTS robot and achieved a throughput in excess of 100,000 data points per day. A protocol for a fully automated high throughput IC50 determination was developed for hit validation. The basic 1536 well screening platform reported here is simple, robust and cost effective. It is widely applicable to any protein-protein interaction of therapeutic interest.

The invention provides a yeast two-hybrid method. The yeast two-hybrid method is characterized by comprising the steps that 1, library yeast is activated, and an AD-Y fusion vector is transformed intothe library yeast; 2, bait plasmids BD-X are transformed into yeast cells Y2H Gold; 3, recombined yeast of BD-X and recombined yeast containing the AD-Y are fused into a diploid, the diploid yeast iscultured on an amplification culture medium containing zinc ions to obtain a bacterial colony, and then positive clone screening is conducted. GAL4 protein in the yeast cells Y2H Gold used in the method is a dependent transcription factor of the zinc ions, therefore, the zinc ions are added into the amplification culture medium used in the method, interactions between low-abundance proteins are improved, the detection rate of low-interaction proteins is improved, and the positive clone rate is improved.

The invention discloses a library versus library yeast two-hybrid massive interaction protein screening method. The method takes a genome-grade cDNA as the bait to screen the genome-grade cDNA library. In the application process of the method, the cDNA library is subjected to a homogenization treatment so as to reduce the masking effect of the high-abundance interaction proteins to the low-abundance interaction proteins, and thus the screening efficiency is improved; and moreover the characteristic of yeast URA3 gene is utilized so as to automatically remove the sequences, which have the self-activating function, in bait cDNA. The invention establish a library versus library yeast two-hybrid massive interaction protein screening method, which has the advantages of high feasibility, low cost, low requirements on experiment conditions, and low workload; and successfully applies the method to a screening of pathogen-host plant interaction proteins.

Protein-protein interaction (PPI) is important for all biological processes; therefore, the research of protein interaction is always a research hot in the fields of cell biology and molecular biology. The co-immunoprecipitation (CoIP) is a classic method which is used to research protein interaction based on the specific action between antibody and antigen and is the commonest and most effectivemethod to find and testify PPI; the traditional CoIP steps based on a resin are complicated and labor consuming and are hard to realize the flux detection. The key point in the invention is that CoIPis implemented on glass aldehyde sheet of the fixed anti-label antibody by utilizing the epitope label of recombinant protein; protein-protein interaction (PPI) is detected by the antibody labeled byfluorescence. The method greatly simplifies the operation steps of the traditional CoIP, greatly improves the flux of sample detection and is a novel technique platform to research PPI simply, conveniently and swiftly and with high flux.

The invention relates to application of IPCEF1 (Interaction Protein For Cytohesin Exchange Factors 1) in diagnosing and treating osteosarcoma. In recent years, the treatment of the osteosarcoma encounters the bottleneck, and particularly in an aspect of early diagnosis of osteosarcoma transfer, a related molecular tumor marker is clinically in urgent need. Osteosarcoma case samples are collected for carrying out high-throughput sequencing by an inventor, genes IPCEF1 which are closely related to the osteosarcoma are picked out by adopting bioinformatics analysis, the relevance of the IPCEF1 and the osteosarcoma is verified in a large sample through a molecular biology experiment, the molecular biology experiment shows that the genes IPCEF1 are expected to be a diagnosis molecular marker of the osteosarcoma, and an ideal is provided for early diagnosis of the osteosarcoma.

The invention discloses a complete set of reagents for detecting interaction between protein subjected to post-translational modification and ligands thereof. The complete set of reagents consists offour reagents A, B, C and D, wherein A is formed by connecting a biomolecule named as R and a protein named as X; B contains a biomolecule named as L; R and L are the same or different and have interaction, and phase change occurs after the R and L interact; C is a polymer formed by a monomer C, the monomer C is a molecule obtained by connecting a monomer named as mc, a reporter group named as I and a biomolecule named as YC, and two or more mc can form the polymer; D is formed by connecting a modified protein named as XL and a biomolecule named as YD; and the YC and the YD have interaction. According to the invention, high enrichment of the interaction protein and the ligand in the phase-change liquid drop is realized, and the weak interaction signal is amplified, so that the detection iseasy.

The present invention provides a method for modulating an expression level of a gene encoding slow myosin in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a nuclear receptor interaction protein (NRIP) and a pharmaceutically acceptable carrier. The present invention also provides a method for modulating an expression level of a gene encoding slow myosin in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of an expression vector comprising a gene encoding a nuclear receptor interaction protein (NRIP) and a pharmaceutically acceptable carrier. In a preferred embodiment, the expression vector is an adenoviral vector.